文献速递分子诊断临床免疫质量管理与危急值

尿液游离DNA片段组学检测多种泌尿系统癌症并可能减少不必要的前列腺活检

Urinary Cell-Free DNA Fragmentomics Detects Multiple Urologic Cancers and May Reduce Unnecessary Prostate Biopsies.
PubMed 文献 · Clin Chem · 2026-09-25

本研究开发了基于片段组学的尿液游离DNA甲基化分析技术uFRAGMA,利用400例膀胱癌、前列腺癌、肾癌及非癌受试者的尿液样本评估其性能。结果显示,uFRAGMA检测膀胱癌的AUC为0.98,检测肾癌的AUC为0.93,在前列腺特异性抗原(PSA)升高(>4 ng/mL)人群中可能减少67.5%的不必要前列腺活检,肿瘤起源分类器准确率为71%至92%。

要点

  • uFRAGMA检测膀胱癌AUC达0.98,检测肾癌AUC达0.93。
  • 在PSA>4 ng/mL人群中可能减少67.5%不必要前列腺活检。
  • 肿瘤起源分类器对泌尿系统恶性肿瘤分类准确率为71%至92%。

核心结论

  • uFRAGMA对尿液游离DNA的片段组学分析可能为泌尿系统癌症的无创检测、定位和风险分层提供临床上有意义的策略,并有望减少不必要的组织活检。

研究设计与样本

  • 本研究为概念验证研究,开发了基于片段组学的尿液游离DNA甲基化分析技术uFRAGMA,并使用400例膀胱癌、前列腺癌、肾癌及非癌受试者的尿液游离DNA样本评估其性能。

主要发现

  • uFRAGMA检测膀胱癌的AUC为0.98,检测肾癌的AUC为0.93。
  • 在PSA>4 ng/mL的前列腺癌筛查人群中,uFRAGMA可能减少67.5%的不必要前列腺活检。
  • 肿瘤起源分类器对泌尿系统恶性肿瘤的分类准确率为71%至92%。

关键数值与推荐

  • 膀胱癌检测AUC为0.98。
  • 肾癌检测AUC为0.93。
  • 在PSA>4 ng/mL人群中可能减少67.5%的不必要前列腺活检。
  • 肿瘤起源分类器准确率为71%至92%。

临床怎么用

  • uFRAGMA可能作为无创策略用于泌尿系统癌症的检测、定位和风险分层,并可能减少不必要的前列腺活检。

局限性

  • 本研究为概念验证研究,其临床效用仍需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Urinary cell-free DNA (ucfDNA) represents a completely noninvasive yet underutilized biospecimen for molecular diagnostics. Our group previously demonstrated that fragmentomic features of plasma cell-free DNA enable direct inference of underlying DNA methylation signals. However, the relationship between DNA methylation and fragmentomic patterns in urine, as well as their potential clinical utility, remains unexplored. METHODS: We developed FRAGmentomics-based Methylation Analysis for ucfDNA (termed uFRAGMA) and evaluated its performance using 400 ucfDNA samples from patients with bladder, prostate, and kidney cancers, as well as non-cancer subjects. The ucfDNA fragmentation patterns around cancer-associated cytosine-phosphate-guanine (CpG) sites were used for cancer detection and differentiation. RESULTS: uFRAGMA demonstrated robust diagnostic performance across urological malignancies, achieving an area under the curve (AUC) of 0.98 for bladder cancer detection and 0.93 for kidney cancer detection. In the context of prostate cancer screening, uFRAGMA could potentially reduce unnecessary prostate biopsies by 67.5% among patients with elevated prostate-specific antigen (PSA) levels (>4 ng/mL), who would otherwise be at risk of overtreatment. Furthermore, we developed a tumor-of-origin classifier for urologic malignancies, attaining classification accuracies ranging from 71% to 92%. CONCLUSIONS: Our findings from this proof-of-concept study suggest that fragmentomics analysis of ucfDNA may provide a clinically meaningful, noninvasive strategy for cancer detection, localization, and risk stratification of urologic cancers, with potential to refine existing clinical practices and reduce unnecessary tissue biopsies.

来源:Clin Chem,查看原文。版权归原作者所有。

引用

  1. Zhou Q, Jiang P, Kang G, et al. Urinary Cell-Free DNA Fragmentomics Detects Multiple Urologic Cancers and May Reduce Unnecessary Prostate Biopsies. Clin Chem. 2026. PMID: 42789091. doi:10.1093/clinchem/hvag124

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。